Roseway Labs and Mast Cell Action Unite to Advance MCAS Education

Leading UK compounding pharmacy Roseway Labs has officially announced a strategic partnership with Mast Cell Action, a UK-based charity dedicated to supporting individuals affected by Mast Cell Activation Syndrome (MCAS) and improving awareness of mast cell disorders.

The formal agreement follows over a year of successful collaboration between the two organisations and signals a shared commitment to improving outcomes for patients living with complex mast cell conditions. By strengthening their alignment, the partnership aims to expand joint initiatives and deliver greater impact across both patient and clinical communities.

At its core, the collaboration will focus on increasing awareness and understanding of mast cell disorders, including MCAS, hereditary alpha-tryptasemia (HαT), and mastocytosis, through enhanced education, professional engagement, and clinical support.

A key initiative within this partnership is an upcoming educational webinar, “Mast Cell Disorders in Practice: MCAS, HαT and Mastocytosis,” taking place on 18 June 2026 (12:30–13:30) in recognition of MCAS Awareness Month.

The session will bring together expert voices from both organisations, alongside leading clinicians including Dr. Bethan Myers, Consultant Haematologist. The webinar aims to deliver evidence-based insights to healthcare professionals, supporting earlier recognition, improved diagnosis, and more personalised patient care.

Mast cell disorders are a group of conditions in which mast cells – key components of the immune system – become overactive or are present in excessive numbers. This can result in recurrent or unexplained allergic-type symptoms affecting multiple systems in the body.

Among the most recognised conditions are MCAS, mastocytosis, and HαT. MCAS in particular is a multi-system disorder characterised by the inappropriate release of mast cell mediators, often triggered by factors such as certain foods, environmental chemicals, stress, exercise, or temperature changes.

Symptoms and triggers vary widely between individuals, making diagnosis complex. While historically considered rare, mast cell disorders are increasingly being identified in clinical practice. Emerging research suggests MCAS may affect up to 17% of the population, although further studies are needed to fully understand its prevalence and mechanisms.

For many patients with MCAS, sensitivities extend beyond environmental triggers to include ingredients commonly found in standard medications such as dyes, fillers, preservatives, and coatings. This presents a significant challenge in treatment.

Compounding pharmacies like Roseway Labs play a critical role in addressing this gap. By creating customised formulations tailored to individual patient needs, they can minimise exposure to problematic substances and improve treatment tolerability.

Elizabeth Philp, CEO of Roseway Labs, explains: “We’re delighted to partner with Mast Cell Action, building on a relationship that has already made a meaningful difference to patients living with MCAS. At Roseway Labs, we believe individualised healthcare should be accessible to all patients, particularly those with complex conditions.

“Many patients with MCAS experience sensitivities to standard medicines and require a more tailored treatment approach. Our pharmacy compounds medicines free from common allergens and irritants, supporting clinicians with bespoke solutions that improve tolerability and patient outcomes.”

Mast Cell Action has long been a vital resource for individuals navigating life with mast cell disorders, offering community-led support, education, and advocacy.

CEO Joy Mason highlights the significance of formalising the partnership.

She said: “We’re pleased to be formalising our partnership with Roseway Labs following a year of positive collaboration. By working together, we can strengthen awareness and understanding of mast cell disorders and provide better support for both patients and healthcare professionals.

“Education is key to improving recognition, enabling quicker diagnosis and better care, and this partnership allows us to expand our reach and impact across the UK.”

Despite increasing recognition, mast cell disorders remain underdiagnosed and frequently misunderstood. Their broad and variable symptom profiles often overlap with other conditions, contributing to delays in diagnosis and treatment.

Dr. Bethan Myers commented: “Education and awareness are essential to improving outcomes for patients with mast cell disorders, which can be complex and challenging to diagnose and manage.

“There is now a significant and growing body of information to support patients with MCAS. Initiatives such as this webinar provide an important opportunity to share evidence-based insights and help clinicians recognise these conditions earlier, understand patient variability, and deliver more individualised care.”